| Sep 9 |
Fulcrum rises after BofA upgrades rating on chance of FSHD study success
|
| Sep 5 |
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
|
| Aug 30 |
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
|
| Aug 30 |
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
|
| Aug 29 |
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
|
| Aug 28 |
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
|
| Aug 28 |
One Fulcrum Therapeutics Insider Raised Their Stake In The Previous Year
|
| Aug 28 |
Addex Stock Soars on Crucial Update From Indivior Research Deal
|
| Aug 28 |
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
|
| Aug 27 |
Fulcrum Therapeutics to Participate in Upcoming September Conferences
|
